Business
Equillium Announces Poster Presentation at the Annual Meeting of The American Association of Immunologists
CD6 contributes to cell adhesion/migration both through direct ligand interactions with activated leukocyte cell adhesion molecule (ALCAM) and through the
About this update from Equillium, Inc.
[{"type":"text","content":"\nCD6 contributes to cell adhesion/migration both through direct ligand interactions with activated leukocyte cell adhesion molecule (ALCAM) and through the stabilization of cell membrane VLA4\n\n\nBlockade of CD6 through itolizumab prevents the trans-endothelial migration of effector T cells\n\n\nData supports the differentiated mechanism of action of itolizumab\n\n\n LA JOLLA, Calif.--(BUSINESS WIRE)--\nEquillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that a poster was presented at IMMUNOLOGY2024, the annual meeting of The American Association of Immunologists. The meetings are taking place at McCormick Place Convention Center in Chicago, Illinois, May 3 – 7.\n\n\n“Our data demonstrates that CD6 contributes to cell adhesion/migration both through direct ligand interactions with ALCAM and through the stabilization of cell membrane VLA4, and that these functions can be abrogated by itolizumab,” said Dr. Stephen Connelly, chief scientific officer at Equillium. “We previously showed that blockade of CD6 prevents the trans-endothelial migration of effector T cells and this new data further elucidates the molecular mechanism. Moreover, our data continues to demonstrate that increased levels of CD6 facilitate the migration of pathogenic effector T cells into inflamed tissues and that itolizumab can modulate not only their activity, but trafficking too.”\n\n\nTitle: Surface CD6 regulates T cell adhesion and migration through direct ligand interaction and stabilization of VLA4\nLead Author: Valeria Marrocco, Senior Scientist, Equillium, Inc.\nPresentation Type: Poster Session\nPoster Number: P713\nAbstract ID: 4364\nSession Title: Migration and Adhesion in Inflammation, Cancer, and Metabolic Disorders\n\n\nKey Highlights, Summaries & Conclusions from Presentation:\n\n\n\nItolizumab not only blocks the binding of CD6 to ALCAM, but it also induces the stripping of the receptor on the T cells’ membrane in the presence of antigen presenting cells, generating CD6 low T cells.\n\n\n\nReduction of CD6 on T cells or blocking of ALCAM on the human umbilical vein endothelial cells (HUVEC), prevents the adhesion of Effector T cells to the endothelial monolayer.\n\n\n\nItolizumab treatment significantly reduced the tr...